関連する実験動画

Updated: Aug 31, 2026

Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

プロスタグランジンE1が補助性関節炎に及ぼす影響

R B Zurier, F Quagliata

    Nature
    |December 3, 1971
    PubMed
    まとめ

    No abstract available in PubMed .

    さらに関連する動画

    Spontaneous and Evoked Measures of Pain in Murine Models of Monoarticular Knee Pain
    08:03

    Spontaneous and Evoked Measures of Pain in Murine Models of Monoarticular Knee Pain

    Published on: February 22, 2019

    Murine Model of Epicutaneously-Induced Immunomodulation
    09:07

    Murine Model of Epicutaneously-Induced Immunomodulation

    Published on: June 24, 2025

    関連する実験動画

    Last Updated: Aug 31, 2026

    Development of Recombinant Proteins to Treat Chronic Pain
    10:37

    Development of Recombinant Proteins to Treat Chronic Pain

    Published on: April 11, 2018

    Spontaneous and Evoked Measures of Pain in Murine Models of Monoarticular Knee Pain
    08:03

    Spontaneous and Evoked Measures of Pain in Murine Models of Monoarticular Knee Pain

    Published on: February 22, 2019

    Murine Model of Epicutaneously-Induced Immunomodulation
    09:07

    Murine Model of Epicutaneously-Induced Immunomodulation

    Published on: June 24, 2025

    関連する概念動画

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

    Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

    The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
    Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    JoVEについて
    概要リーダーシップブログJoVEヘルプセンター
    著者向け
    出版プロセス編集委員会範囲と方針査読よくある質問投稿
    図書館員向け
    推薦の声購読アクセスリソース図書館諮問委員会よくある質問
    研究
    JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
    教育
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
    利用規約
    プライバシーポリシー
    ポリシー
    Jove
    Visualize
    お問い合わせ